Blackrock Health Sciences Trust (BME)

FairStock Score: 54/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach BlackRock Health Sciences Trust as a closed-end fund, not an operating business. It owns a portfolio of health-sciences equities, so its value rises or falls with those holdings, not with factories or brands. The fund has no traditional moat; its edge, if any, is BlackRock's research and the portfolio managers' discipline. At the close on 2026-10-13, the price was $43.83. FairStock calculations show a P/E of 5.44, P/B of 0.99, and a dividend yield of 7.07%. The Graham Number of $89.30 suggests a 50.92% margin of safety, which catches my eye. A beta of 0.58 and D/E of 0.00 imply low volatility and no balance-sheet leverage. ROE is 19.27%, which looks strong on its face. But other quality signals are poor. ROCE of 0.20% is near zero, the Piotroski F-Score is just 1/9, and the FairStock Score is 54/100. Revenue and profit growth are not available, and the Lynch category is none because there are only zero years of filed results—not enough history for a three-year classification. That lack of a track record matters. I cannot judge earnings durability, distribution coverage, or whether the fund is shrinking or growing. The Altman Z-Score of 166.54 is enormous, but that metric is not naturally suited to a closed-end fund, so I would not lean on it. Valuation looks cheap against the Graham Number and modestly below book, but a value investor must ask whether the portfolio's earnings are real and recurring. With a weak F-Score and almost no ROCE, I would demand a wider discount or clearer evidence that the distribution is well covered before calling it a compelling bargain.

In plain English: BlackRock Health Sciences Trust is a closed-end fund that invests in health-care and life-sciences companies. The numbers show it pays a high income, trades near the accounting value of its assets, and looks inexpensive against one accounting-based estimate, but the quality signals are weak and there is little track record. Overall, the price looks roughly fair to somewhat cheap compared with the figures, not clearly expensive.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer